Analysts Set Solventum Corporation (NYSE:SOLV) PT at $91.64

Solventum Corporation (NYSE:SOLV) has been given a consensus recommendation of “Moderate Buy” by the thirteen brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $91.6364.

Several research analysts recently weighed in on the company. Stifel Nicolaus raised their target price on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. BMO Capital Markets started coverage on shares of Solventum in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target on the stock. Piper Sandler upped their price target on shares of Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Wedbush raised their price objective on shares of Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Finally, Mizuho set a $113.00 price objective on shares of Solventum in a research note on Thursday, August 6th.

Solventum Price Performance

Shares of NYSE:SOLV opened at $91.70 on Wednesday. The stock has a market cap of $15.61 billion, a price-to-earnings ratio of 11.21, a PEG ratio of 1.43 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. Solventum has a 12 month low of $62.38 and a 12 month high of $94.16. The stock’s 50 day moving average price is $84.00 and its 200 day moving average price is $76.02.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The firm had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same period last year, the company posted $1.69 EPS. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts anticipate that Solventum will post 7.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Solventum

A number of institutional investors and hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System raised its holdings in Solventum by 5,434.1% during the 2nd quarter. California State Teachers Retirement System now owns 13,234,928 shares of the company’s stock worth $1,021,075,000 after buying an additional 12,995,776 shares during the period. Independent Franchise Partners LLP boosted its holdings in shares of Solventum by 19.0% in the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after buying an additional 2,456,451 shares during the period. Diamond Hill Capital Management LLC Investment Advisor purchased a new position in shares of Solventum in the second quarter worth approximately $150,066,000. Norges Bank purchased a new position in shares of Solventum in the fourth quarter worth approximately $147,467,000. Finally, Diamond Hill Capital Management Inc. grew its position in Solventum by 152.2% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock worth $167,119,000 after purchasing an additional 1,272,921 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.